LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

7.42 -2.62

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.42

Max

7.93

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Pelnas, tenkantis vienai akcijai	-0.12
Pelno marža	-13,764.773
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+70.03% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	54M 627M
Ankstesnė atidarymo kaina	10.04
Ankstesnė uždarymo kaina	7.42

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-19 17:29; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025-12-19 16:47; UTC

Pagrindinės rinkos jėgos

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025-12-19 16:10; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025-12-19 22:33; UTC

Uždarbis

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025-12-19 22:19; UTC

Uždarbis

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-19 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 21:44; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 21:38; UTC

Uždarbis

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025-12-19 21:00; UTC

Rinkos pokalbiai

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025-12-19 20:23; UTC

Rinkos pokalbiai

Oil Futures End Down Week on Up Note -- Market Talk

2025-12-19 20:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025-12-19 18:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025-12-19 18:00; UTC

Rinkos pokalbiai

Uždarbis

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025-12-19 17:41; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 17:24; UTC

Rinkos pokalbiai

Uždarbis

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-19 16:29; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025-12-19 16:20; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025-12-19 16:19; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025-12-19 16:18; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025-12-19 16:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-19 16:16; UTC

Rinkos pokalbiai

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025-12-19 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 16:04; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 15:37; UTC

Rinkos pokalbiai

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025-12-19 15:21; UTC

Rinkos pokalbiai

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Gold Flat But Set for Weekly Gains -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-19 15:09; UTC

Uždarbis

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

70.03% į viršų

12 mėnesių prognozė

Vidutinis 13.33 USD 70.03%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.